What does Assembly Biosciences do?
Assembly Biosciences, Inc. is a clinical-stage biotechnology company listed on Nasdaq under ASMB. It develops oral small-molecule therapies for serious viral and liver diseases and has no approved products. The company reports one operating segment, while its value is concentrated in clinical programs, data quality, and the Gilead Sciences collaboration. Its pipeline overview groups the portfolio around herpesviruses, viral hepatitis, and research-stage antiviral targets.
A focused antiviral developer, not a diversified pharmaceutical company
The portfolio centers on ABI-6250, an oral NTCP inhibitor being advanced for chronic hepatitis delta virus, or HDV. In May 2026, Assembly Bio also planned Phase 2 development in primary biliary cholangitis and primary sclerosing cholangitis for Q1 2027. Other assets include the Gilead-licensed herpes inhibitors ABI-5366 and ABI-1179, the HBV capsid assembly modulator ABI-4334, and the transplant-associated herpesvirus polymerase inhibitor ABI-7272.
| Research dimension | Assembly Bio position | Why it matters |
|---|---|---|
| Industry | Clinical-stage biotechnology; antiviral and liver-disease therapeutics | Value depends on development probability, time, cost, and commercial economics rather than current product margins. |
| Customers today | Gilead is the collaboration customer and source of all FY2025 revenue | Reported revenue is concentrated and milestone-driven, not a diversified recurring sales base. |
| Core capabilities | Virology discovery, medicinal chemistry, translational development, and early clinical execution | The company’s advantage must be judged through differentiated molecules and data quality. |
| Geography | U.S.-based operations with global clinical and regulatory ambitions | Commercial value can be global, but development and privacy rules span multiple jurisdictions. |
How does Assembly Biosciences make money without approved products?
Assembly Bio converts scientific work and program rights into collaboration revenue, option fees, equity capital, and potential milestones, royalties, or profit share. It has no product-sales base. Consequently, a strong revenue year may reflect a license payment, while a weaker quarter may reflect research-service timing rather than a change in drug potential.
The Gilead collaboration is both a revenue engine and a strategic dependency
The 12-year Gilead collaboration, established in October 2023, combines funded research, contributed programs, equity investment, and options over Assembly Bio assets. Option fees generally range from $45 million to $125 million. In December 2025, Gilead exercised its option on ABI-5366 and ABI-1179, producing a net $35 million payment after a $10 million funding credit. The mechanics are detailed in the 2025 Form 10-K.
What did FY2025 revenue actually represent?
FY2025 collaboration revenue was $72.3 million. Of that amount, $37.3 million came from research and development services and $35.0 million from the HPI license transfer. The following mix is therefore an accounting picture of the year, not a product mix.
Which pipeline programs matter most?
Each program has different ownership, stage, funding needs, competitive pressure, and valuation economics. One-segment accounting therefore does not make the assets economically interchangeable.
ABI-6250 has become the principal independently controlled value driver
ABI-6250 combines an oral mechanism with several potential indications. NTCP is both an HDV entry receptor and a bile-acid transporter, linking viral hepatitis with cholestatic disease. The company’s May 2026 development update widened the opportunity but added trials, endpoints, and funding decisions.
The herpes program now tests partnership economics rather than only science
After Gilead exercised its option on ABI-5366 and ABI-1179, the main question became retained economics and capital commitment. Assembly Bio may elect a 40% U.S. cost-profit share instead of U.S. milestones and royalties. That choice could preserve more upside, but it would also expose the company to substantial development and commercialization costs.
What does the latest reporting period show?
The latest full statements cover the quarter ended March 31, 2026. Assembly Bio completed HPI Phase 1b follow-up and ABI-6250 chronic toxicology work. The financial picture remained that of a well-capitalized, loss-making developer whose revenue depends on Gilead research activity.
Revenue declined, but the quarter is better read through expense and liquidity trends
Q1 2026 collaboration revenue declined 12.8% from $9.4 million to $8.2 million as Gilead service timing changed. R&D expense held at $14.9 million; G&A rose to $4.7 million from $4.5 million. Operating loss widened to $11.4 million from $9.9 million, partly offset by $2.3 million of interest and other income.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Collaboration revenue | $8.2M | $9.4M | Timing-sensitive research-service revenue, not product demand. |
| R&D expense | $14.9M | $14.9M | Portfolio spending was stable as completed trials offset higher personnel and discovery activity. |
| G&A expense | $4.7M | $4.5M | Increase was mainly related to stock-based compensation for performance awards. |
| Operating loss | $11.4M | $9.9M | The collaboration did not cover the full clinical and corporate cost base. |
| Net loss per share | $0.54 | $1.17 | Lower per-share loss largely reflects the weighted-average share count rising to 16.9M from 7.5M. |
| Current assets / liabilities | $232.6M / $35.0M | Not comparable here | A current ratio of about 6.6x indicates strong near-term liquidity before the May financing. |
The post-quarter offering sold 3,924,624 common shares and pre-funded warrants for 415,000 shares at approximately $26.50 per security. The closing announcement directed the proceeds to pipeline development and general corporate purposes; they were not included in the March 31 balance sheet.
Which turning points shaped Assembly Bio’s current strategy?
Assembly Bio’s history reflects repeated strategic resets: a corporate identity change, concentration on antiviral science, portfolio pruning, and deeper Gilead integration. Those choices explain today’s liquidity, partnership concentration, and split between independently controlled and licensed programs.
-
2005–2007The company was incorporated as South Island Biosciences and renamed Ventrus Biosciences, establishing the public corporate shell that later housed the antiviral strategy.
-
2014Ventrus acquired private Assembly Pharmaceuticals and adopted the Assembly Biosciences name, making HBV-focused science central to the business.
-
2023Assembly Bio entered the Gilead collaboration, receiving $100.0M of initial proceeds and gaining access to HPI and NNPI programs while granting broad opt-in rights.
-
2024Clinical development accelerated across ABI-5366, ABI-1179, ABI-6250, and ABI-4334; a collaboration amendment supplied $10.0M of accelerated funding.
-
2025Multiple positive Phase 1 readouts arrived, a large equity financing strengthened liquidity, and Gilead licensed the HPI program for a net $35.0M fee.
-
2026ABI-6250 moved toward Phase 2 and expanded into PBC and PSC; a further $115.0M gross equity raise increased capacity to fund broader development.
The strategic tension is independence versus partnered scale
Gilead supplies capital, scientific assets, development credibility, and a commercialization path that a 73-person biotech could not readily replicate. In return, it holds option rights and influence over important programs. Assembly Bio therefore operates between an independent biotech and a partner-funded discovery platform, retaining meaningful economics but less strategic autonomy.
How strong is the balance sheet and capital allocation position?
Cash, equivalents, and marketable securities rose from $112.1 million at December 31, 2024 to $248.1 million at December 31, 2025, then fell to $226.6 million at March 31, 2026 as operations consumed cash. The May offering subsequently added $115.0 million of gross proceeds.
FY2025 was financially unusual because collaboration revenue offset much of the loss
| Metric | FY2025 | FY2024 | Analytical meaning |
|---|---|---|---|
| Collaboration revenue | $72.3M | $28.5M | 154% growth was driven largely by the $35.0M HPI license recognition. |
| R&D expense | $64.8M | $55.9M | A 16% increase reflects higher clinical activity, especially for the HPI program. |
| G&A expense | $19.6M | $18.0M | Corporate cost growth was moderate relative to program spending. |
| Net loss | $6.1M | $40.2M | The improvement should not be treated as evidence of sustainable profitability. |
| Operating cash use | $41.1M | $51.1M | Cash use improved because Gilead cash receipts partly funded higher expenses. |
| Financing cash inflow | $174.7M | $29.4M | Equity financing, not operating cash generation, produced the liquidity step-up. |
Where did research capital go?
Who owns Assembly Biosciences and how does Gilead influence governance?
Assembly Bio has one common share class with one vote per share, yet its investor base is unusually strategic. The April 2026 proxy disclosed five holders above 5%, led by Gilead, which also may designate two directors or board observers. Economic ownership, program rights, and governance influence are therefore linked.
| Holder or group | Beneficial ownership | Proxy-date stake | Why it matters |
|---|---|---|---|
| Gilead Sciences | 4,505,391 shares | 28.3% | Strategic partner, major investor, and holder of two board-designation rights. |
| Commodore Capital affiliates | 1,615,981 shares | 9.8% | Specialist healthcare capital with meaningful exposure to clinical milestones. |
| RA Capital affiliates | 1,530,615 shares | 9.3% | Another biotechnology-focused investor, reinforcing a specialist holder base. |
| Janus Henderson affiliates | 1,341,508 shares | 8.4% | Adds diversified institutional ownership beyond dedicated biotech funds. |
| Farallon affiliates | 1,227,590 shares | 7.7% | Represents another sophisticated institutional holder with warrant exposure. |
| Directors and executive officers | 559,025 shares | 3.5% | Management has economic alignment, but does not control the vote. |
Source period: 15,892,608 common shares outstanding on April 10, 2026, as reported in the 2026 proxy statement.
The May financing changed the share base after the proxy snapshot
The proxy percentages became stale after the May financing. Gilead bought 471,698 shares and reported 4,977,089 shares afterward in a Form 4, while Assembly Bio issued additional common shares and pre-funded warrants to other investors. The larger cash base came with a larger diluted share count, which must be reflected in per-share valuation.
What gives Assembly Bio a competitive edge—and where is it vulnerable?
Assembly Bio lacks a commercial moat based on brand, distribution, or manufacturing scale. Its prospective advantage comes from antiviral chemistry, long-acting oral profiles, differentiated mechanisms, intellectual property, focused execution, and Gilead validation. Those resources become durable only if clinical benefit, approval, and defensible labeling are established.
Differentiation is molecule-specific
ABI-5366 and ABI-1179 are designed for weekly oral dosing, with ABI-5366 also tested monthly. If larger trials confirm efficacy and safety, that convenience could differentiate them from daily therapies. ABI-6250 offers an oral HDV-entry mechanism and a second route into cholestatic disease. The company’s scientific publications show the mechanistic evidence behind these programs, but clinical outcomes remain decisive.
| Competitive source | Officially disclosed examples | Assembly Bio angle | Pressure point |
|---|---|---|---|
| Named companies across the portfolio | GSK, Enanta, Arbutus, Vir Bio, Mirum, Huahui Health, Aligos, Innovative Molecules, and AiCuris / Asahi Kasei | Long-acting oral profiles and differentiated antiviral mechanisms | The filing notes that rival approaches may be similar or entirely different; exact program overlap varies. |
| Available HBV treatments | Existing approved therapies, identified as competition in the FY2025 filing | ABI-4334 uses next-generation capsid assembly modulation | Current therapies already serve patients, Gilead declined its option, and Assembly Bio is seeking a partner. |
| Large pharma and smaller biotech | Companies with competing development and commercialization programs | Focused virology execution supported by Gilead | Larger rivals may have more capital, manufacturing capability, regulatory experience, and commercial reach. |
| Academic and public research | Academic institutions, government agencies, and public or private research organizations | Company-controlled intellectual property and clinical-stage programs | New science, patent claims, or collaborative networks can reduce perceived differentiation. |
Which opportunities, risks, and KPIs should researchers monitor?
Clinical transitions, partner decisions, and financing choices matter more than quarterly revenue changes. Researchers should track the evidence produced and the cash required.
Clinical and partner concentration risks dominate
| Risk | Financial line affected | Concrete indicator | Why it can change the story |
|---|---|---|---|
| Clinical failure or delay | R&D expense, asset value, future milestones | Enrollment, safety events, dose response, endpoint achievement | Early data may not replicate in larger or longer patient studies. |
| Gilead dependence | Collaboration revenue and retained economics | Option decisions, development budgets, termination rights | All FY2025 revenue came from one related-party collaborator. |
| Capital intensity and dilution | Cash, equity, per-share value | Operating cash use, trial commitments, new securities | The business has raised capital repeatedly and has no product-sales funding base. |
| Third-party execution | Trial timelines and manufacturing cost | CRO/CMO performance, supply availability, regulatory compliance | Assembly Bio relies on outside organizations for studies and manufacturing. |
| Competitive displacement | Commercial probability and pricing | Rival data, approvals, dosing convenience, resistance profile | A scientifically interesting asset can lose value if a better therapy arrives first. |
| Regulatory and data rules | Development timing and compliance cost | FDA feedback, privacy requirements, trial-data controls | Cross-border studies face evolving clinical, privacy, and health-data obligations. |
A practical KPI framework for a pre-commercial biotech
| KPI | How to calculate or observe it | Assembly Bio interpretation |
|---|---|---|
| Cash runway | Liquid resources divided by normalized annual cash burn, adjusted for planned trials | Management stated funding into 2028 before adding the May 2026 gross proceeds. |
| R&D intensity | R&D expense divided by total operating expense | Q1 2026 R&D was about 76.1% of operating expense, appropriate for a research-led company. |
| Partner concentration | Revenue from largest collaborator divided by total revenue | 100% in FY2025, making diversification and contract durability important. |
| Clinical milestone conversion | Programs advancing on time relative to stated milestones | More informative than quarter-to-quarter accounting revenue. |
| Dilution-adjusted liquidity | Net cash considered alongside fully diluted securities | Cash increased materially, but the share base and warrant overhang also expanded. |
The company’s Q1 2026 results release and the related Form 10-Q are the best recurring sources for updating these indicators.
What is the key takeaway for valuation and research?
Assembly Biosciences is best valued as probability-weighted drug programs plus cash, less future development costs and overhead. Extrapolating FY2025 revenue would be misleading because nearly half came from the HPI license, all revenue came from Gilead, and no product is approved. A useful model separates each program’s stage, indication, ownership, success probability, timing, retained economics, and required investment.
What should a student or investor carry forward?
The strategic trade-off is clear: Assembly Bio has a focused antiviral engine and a powerful partner, but that partner is also its only revenue source, largest strategic shareholder, option holder, and board-designation counterparty. ABI-6250 is the main independently controlled path, while the HPI program offers partnered economics with less control. Cash provides time, but each trial converts liquidity into evidence at an uncertain rate.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.